Redwire Corporation (NYSE: RDW) has appointed two industry veterans to strategic advisory roles at its space pharmaceutical venture, Space Microgravity Development, known as SpaceMD.
SpaceMD is Redwire’s dedicated venture company focused on leveraging the microgravity environment in space for pharmaceutical research and manufacturing purposes.
Paul Reichert, a former Principal Investigator at Merck & Co. Inc. (NYSE: MRK), joins the advisory team bringing deep expertise in drug development and biopharmaceutical research pipelines.
Niki Werkheiser, a former Director of Technology Maturation at NASA’s Space Technology Mission Directorate, rounds out the new advisory additions with significant space technology credentials.
Reichert’s role will center on identifying promising drug candidates and supporting the development of an orbital research and manufacturing pipeline for SpaceMD.
Werkheiser will focus on developing new therapeutic concepts and pharmaceutical research opportunities aboard the International Space Station and emerging commercial platforms.
The appointments signal growing institutional confidence in the commercial potential of space-based pharmaceutical research, a sector attracting increasing attention from both investors and industry insiders.
SpaceMD CEO John Vellinger emphasized the strategic importance of the new advisors in advancing the company’s core objectives in the competitive in-space research market.
“SpaceMD’s mission is to unlock new pharmaceutical drugs through cutting-edge, space-based research. Bringing Paul and Niki onto our advisory team significantly advances that mission,” said Vellinger.
“Their unparalleled expertise in drug development and go-to-market strategy, biopharmaceutical research, and space technology will bolster the momentum already underway as SpaceMD continues to lead the industry in in-space pharmaceutical research,” Vellinger added.
Redwire shares were trading up 3.62% at the time of the announcement, reflecting positive market sentiment around the company’s expanding space pharma ambitions.
The broader space economy continues to attract crossover talent from traditional pharmaceutical and government sectors, as companies race to commercialize unique microgravity research conditions.
